[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil].
To investigate the correlation of pharmacokinetic profiles of mycophenolic acid (MPA) with clinic events in kidney transplant patients treated with mycophenolate mofetil (MMF). Sixty-four kidney transplant patients were treated with the triple immune suppression protocol with cyclosporine, MMF, and prednisone. Before the administration of drugs, and 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 10, and 12 hours after the drug administration peripheral blood samples were collected to detect the plasma MPA concentrations (MPA-C(0)) and draw the concentration-time curve. And 4, 7, 21, and 28 days, and 1.5, 2, 3, and 6 months later peripheral blood samples were collected in the morning before drug administration so as to dynamically measure the plasma MPA concentrations. Clinical events were observed. No side effect or acute rejection episode occurred with the median MPA-C(0) value of 0.74 mg/L. Side effects occurred with the median MPA-C(0) value of 1.32 mg/L. Sixteen case-times demonstrated acute rejection episode with the median MPA-C(0) value of 0.39 mg/L. The incidence rates of different side effects, such as infection, bone marrow depression, and digestive tract symptoms were significantly related to MPA-C(0) dose-dependently. MPA-C(0) may be an appropriate pharmacokinetic monitoring parameter for kidney transplant.